Parambil
Parambil is an AI-powered legal technology company specializing in medical record review software for litigation. Their products include Medical Chronologies, Case Validation, and Case Work Ups, which provide precise, AI-assisted analysis of medical records to support both plaintiffs and defense attorneys. The platform offers unparalleled accuracy, saving time and increasing the correctness of information, enabling legal teams to efficiently generate trusted case details, validate evidence, and prepare for trial. Parambil serves plaintiff and defense law firms, courts, insurance companies, defendants, and litigation finance firms, positioning itself as a neutral third-party vendor focused on factual accuracy and efficiency in complex litigation cases.
Parambil
Parambil is an AI-powered legal technology company specializing in medical record review software for litigation. Their products include Medical Chronologies, Case Validation, and Case Work Ups, which provide precise, AI-assisted analysis of medical records to support both plaintiffs and defense attorneys. The platform offers unparalleled accuracy, saving time and increasing the correctness of information, enabling legal teams to efficiently generate trusted case details, validate evidence, and prepare for trial. Parambil serves plaintiff and defense law firms, courts, insurance companies, defendants, and litigation finance firms, positioning itself as a neutral third-party vendor focused on factual accuracy and efficiency in complex litigation cases.
TL;DR
Company: Parambil — AI-powered medical record review for litigation
Founded: 2023
Headquarters: Nyack, New York
Employees: 10
Known funding: $2.0M pre-seed (Jan 15, 2025) and $6.0M seed (Jan 13, 2026)
Company Overview
Problem Domain
Medical record review and litigation support for mass torts, medical malpractice, catastrophic personal-injury, and other complex litigation.
Founded
2023
Industry
Legal technology / Healthtech
Funding Track Record
$2,000,000
$6,000,000
Seed round included participation from NVP Capital and angel investors.